[go: up one dir, main page]

CY1108599T1 - Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος - Google Patents

Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος

Info

Publication number
CY1108599T1
CY1108599T1 CY20081101367T CY081101367T CY1108599T1 CY 1108599 T1 CY1108599 T1 CY 1108599T1 CY 20081101367 T CY20081101367 T CY 20081101367T CY 081101367 T CY081101367 T CY 081101367T CY 1108599 T1 CY1108599 T1 CY 1108599T1
Authority
CY
Cyprus
Prior art keywords
multiple myeloma
aplidin
treatment
aplidine
medicament
Prior art date
Application number
CY20081101367T
Other languages
English (en)
Inventor
Joseph R Bertino
Daniel Medina
Glynn Thomas Faircloth
Constantine S Mitsiades
Kenneth Anderson
Nicholas Mitsiades
Original Assignee
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, Inc. filed Critical Dana-Farber Cancer Institute, Inc.
Publication of CY1108599T1 publication Critical patent/CY1108599T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η απλιδίνη και τα ανάλογα απλιδίνης χρησιμοποιούνται στην κατασκευή κάποιου φαρμάκου για την αντιμετώπιση του πολλαπλού μυελώματος.
CY20081101367T 2003-03-12 2008-11-26 Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος CY1108599T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45412503P 2003-03-12 2003-03-12
US52029303P 2003-11-14 2003-11-14
EP04720081A EP1603584B1 (en) 2003-03-12 2004-03-12 Aplidine for multiple myeloma treatment

Publications (1)

Publication Number Publication Date
CY1108599T1 true CY1108599T1 (el) 2014-04-09

Family

ID=32994545

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101367T CY1108599T1 (el) 2003-03-12 2008-11-26 Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος

Country Status (20)

Country Link
US (1) US7381703B2 (el)
EP (1) EP1603584B1 (el)
JP (1) JP4584245B2 (el)
KR (1) KR101160320B1 (el)
AT (1) ATE406171T1 (el)
AU (1) AU2004218883B2 (el)
CA (1) CA2519789C (el)
CY (1) CY1108599T1 (el)
DE (1) DE602004016126D1 (el)
DK (1) DK1603584T3 (el)
ES (1) ES2312979T3 (el)
IL (1) IL170136A (el)
MX (1) MXPA05009742A (el)
NO (1) NO334264B1 (el)
NZ (1) NZ541611A (el)
PL (1) PL1603584T3 (el)
PT (1) PT1603584E (el)
RU (1) RU2335294C2 (el)
SI (1) SI1603584T1 (el)
WO (1) WO2004080477A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1045648B (en) * 1999-11-15 2007-09-21 Pharma Mar, S.A. Aplidine treatment of cancers
WO2004080421A2 (en) 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
WO2008080956A1 (en) * 2006-12-29 2008-07-10 Pharma Mar, S.A. Prognostic molecular markers for the cancer therapy with aplidine
US20110123486A1 (en) * 2007-06-25 2011-05-26 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
JP2011500650A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療
AU2009221720A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved anticancer treatments
NZ589270A (en) * 2008-05-16 2011-12-22 Pharma Mar Sa Multiple myeloma treatments
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
EP0048149B1 (en) 1980-09-12 1983-11-30 University of Illinois Foundation Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
WO1995017901A1 (en) * 1993-12-29 1995-07-06 Matrix Pharmaceutical, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
ES2167391T3 (es) * 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
DE69703294T2 (de) * 1996-05-22 2001-05-17 Protarga Inc., Conshohocken Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
ATE208324T1 (de) 1996-07-03 2001-11-15 Paxton C G Ltd Behälter
DK0956033T3 (da) 1996-10-24 2003-10-06 Univ Illinois Totalsyntese af amino-Hip-analogen af didemnin A
ES2262175T3 (es) 1996-10-24 2006-11-16 The Board Of Trustees Of The University Of Illinois Estudios semisinteticos para dar analogos de didemnina.
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
WO1998050048A1 (en) * 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CA2338638C (en) 1998-07-30 2009-03-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
JP2003500360A (ja) 1999-05-25 2003-01-07 ポイント セラピューティクス， インコーポレイテッド ボロプロリン化合物類を含む抗癌剤
HK1045648B (en) * 1999-11-15 2007-09-21 Pharma Mar, S.A. Aplidine treatment of cancers
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
DE60123232T2 (de) 2000-04-07 2007-11-08 Trustees Of The University Of Pennsylvania Tamandarin und didemnin analoga und methoden zu deren herstellung und verwendung
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
WO2002028902A2 (en) * 2000-10-05 2002-04-11 Immunex Corporation Nectin polypeptides, polynucleotides, methods of making and use thereof
DE60111858T2 (de) 2000-10-12 2006-04-20 Pharma Mar, S.A., Tres Cantos BEHANDLUNG VON KREBSERKRANKUNGEN mit APLIDIN IN KOMBINATION MIT CARNITIN ODER ACETYLCARNITIN
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
AU2002219472A1 (en) * 2001-01-02 2002-07-16 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
PT1435991E (pt) 2001-10-19 2009-01-16 Pharma Mar Sa Utilização de aplidina para o tratamento de cancro pancreático
WO2004080421A2 (en) 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments

Also Published As

Publication number Publication date
NO20054668L (no) 2005-10-11
IL170136A (en) 2014-04-30
MXPA05009742A (es) 2006-05-25
ATE406171T1 (de) 2008-09-15
US7381703B2 (en) 2008-06-03
JP2006519828A (ja) 2006-08-31
CA2519789C (en) 2012-07-03
US20060172926A1 (en) 2006-08-03
WO2004080477A1 (en) 2004-09-23
JP4584245B2 (ja) 2010-11-17
PL1603584T3 (pl) 2009-02-27
EP1603584B1 (en) 2008-08-27
WO2004080477A8 (en) 2004-11-11
NZ541611A (en) 2008-04-30
DK1603584T3 (da) 2009-01-05
US20070149445A9 (en) 2007-06-28
RU2335294C2 (ru) 2008-10-10
NO334264B1 (no) 2014-01-20
KR20060006779A (ko) 2006-01-19
KR101160320B1 (ko) 2012-06-26
RU2005131578A (ru) 2006-01-27
AU2004218883A1 (en) 2004-09-23
PT1603584E (pt) 2008-11-21
SI1603584T1 (sl) 2009-02-28
EP1603584A1 (en) 2005-12-14
DE602004016126D1 (de) 2008-10-09
AU2004218883B2 (en) 2009-10-01
CA2519789A1 (en) 2004-09-23
ES2312979T3 (es) 2009-03-01

Similar Documents

Publication Publication Date Title
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
ATE461217T1 (de) Glp-1-verbindungen
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
MY151032A (en) Treatment of tnf? related disorders
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
EA200900344A1 (ru) Циклические ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i
EA200401525A1 (ru) Способы лечения гепатита (варианты )
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
NO20053947D0 (no) Forbedrede antitumorale behandlinger.
DK1558580T3 (da) N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner
DK1537132T3 (da) Salt af mortin-6-glucuronid
ATE428418T1 (de) Mit einem serotonin-transporter zusammenwirkende mittel zur krebsbehandlung
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
DE60313444D1 (de) Vegf-peptide und deren verwendung
ATE484195T1 (de) Gewebe-engineering
ITRM20020308A1 (it) Apparecchiatura per trattamenti terapeutici, e relativo metodo.
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE602005011029D1 (de) Therapeutisches mittel zur behandlung von plasmazellneoplasien
DE602004012759D1 (de) Behandlung von fibrosen
NO20022747L (no) Behandlingsstol
UA2826U (uk) Спосіб лікування розсіяного склерозу